Adagene Analyst Ratings
Adagene Analyst Ratings
While ratings are subjective and will change, the latest Adagene (ADAG) rating was a reiterated with a price target of $0.00 to $5.00. The current price Adagene (ADAG) is trading at is $1.50, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/04/2023 | 233.33% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 09/01/2023 | 233.33% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 04/21/2023 | 233.33% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
| 03/29/2023 | 233.33% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
| 03/21/2023 | 233.33% | HC Wainwright & Co. | → $5 | Reiterates | → Buy |
| 01/24/2023 | 233.33% | Morgan Stanley | $7 → $5 | Maintains | Overweight |
| 12/07/2022 | 233.33% | HC Wainwright & Co. | → $5 | Initiates Coverage On | → Buy |
| 09/09/2022 | 366.67% | Morgan Stanley | $15 → $7 | Maintains | Overweight |
| 02/01/2022 | 900% | Morgan Stanley | $27 → $15 | Maintains | Overweight |
| 01/06/2022 | 1700% | Morgan Stanley | $33 → $27 | Maintains | Overweight |
| 07/16/2021 | 2100% | Morgan Stanley | $34 → $33 | Maintains | Overweight |
| 06/25/2021 | 2604.67% | China Renaissance | → $40.57 | Initiates Coverage On | → Buy |
| 03/08/2021 | 2100% | Jefferies | → $33 | Initiates Coverage On | → Buy |
| 03/08/2021 | 2166.67% | Morgan Stanley | → $34 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/04/2023 | 233.33% | HC Wainwright公司 | →$5 | 重申 | 購買→購買 |
| 09/01/2023 | 233.33% | HC Wainwright公司 | →$5 | 重申 | 購買→購買 |
| 04/21/2023 | 233.33% | HC Wainwright公司 | →$5 | 重申 | →購買 |
| 03/29/2023 | 233.33% | HC Wainwright公司 | →$5 | 重申 | →購買 |
| 03/21/2023 | 233.33% | HC Wainwright公司 | →$5 | 重申 | →購買 |
| 01/24/2023 | 233.33% | 摩根士丹利 | $7→$5 | 維護 | 超重 |
| 12/07/2022 | 233.33% | HC Wainwright公司 | →$5 | 開始承保 | →購買 |
| 09/09/2022 | 366.67% | 摩根士丹利 | $15→$7 | 維護 | 超重 |
| 02/01/2022 | 900% | 摩根士丹利 | $27→$15 | 維護 | 超重 |
| 01/06/2022 | 1700% | 摩根士丹利 | $33→$27 | 維護 | 超重 |
| 07/16/2021 | 2100% | 摩根士丹利 | $34→$33 | 維護 | 超重 |
| 2021/06/25 | 2604.67% | 中國文藝復興 | →$40.57 | 開始承保 | →購買 |
| 03/08/2021 | 2100% | 傑富瑞 | →$33 | 開始承保 | →購買 |
| 03/08/2021 | 2166.67% | 摩根士丹利 | →$34 | 開始承保 | →超重 |
What is the target price for Adagene (ADAG)?
天演藥業的目標價是多少？
The latest price target for Adagene (NASDAQ: ADAG) was reported by HC Wainwright & Co. on October 4, 2023. The analyst firm set a price target for $5.00 expecting ADAG to rise to within 12 months (a possible 233.33% upside). 7 analyst firms have reported ratings in the last year.
天演藥業(納斯達克代碼：ADAG)的最新目標價是由HC Wainwright&Co.於2023年10月4日報道的。這家分析公司將目標價定為5美元，預計ADAG將在12個月內升至(可能上漲233.33%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Adagene (ADAG)?
分析師對天演藥業的最新評級是多少？
The latest analyst rating for Adagene (NASDAQ: ADAG) was provided by HC Wainwright & Co., and Adagene reiterated their buy rating.
分析師對天演藥業(納斯達克代碼：ADAG)的最新評級由HC Wainwright&Co.提供，天演藥業重申其買入評級。
When is the next analyst rating going to be posted or updated for Adagene (ADAG)?
下一次分析師對天演藥業的評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adagene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adagene was filed on October 4, 2023 so you should expect the next rating to be made available sometime around October 4, 2024.
分析師是在做了大量研究後才得出股票評級的，這些研究包括查閱公開的財務報表，與天演藥業的高管和客戶交談，以及收聽財報電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。天演藥業的上一次評級是在2023年10月4日提交的，因此你應該預計下一次評級將在2024年10月4日左右公佈。
Is the Analyst Rating Adagene (ADAG) correct?
分析師對天演藥業的評級正確嗎？
While ratings are subjective and will change, the latest Adagene (ADAG) rating was a reiterated with a price target of $0.00 to $5.00. The current price Adagene (ADAG) is trading at is $1.50, which is within the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的天演藥業(ADAG)評級被重申，目標價在0.00美元到5.00美元之間。天演藥業目前的交易價格為1.5美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。
